Eris Lifesciences Limited - Asset Resilience Ratio

Latest as of March 2026: 0.29%

Eris Lifesciences Limited (ERIS) has an Asset Resilience Ratio of 0.29% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Eris Lifesciences Limited short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

Rs216.40 Million

≈ $2.34 Million USD Cash + Short-term Investments

Total Assets

Rs73.66 Billion

≈ $796.55 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2012–2026)

This chart shows how Eris Lifesciences Limited's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see ERIS current and non-current assets.

Liquid Assets Composition Over Time

This chart breaks down Eris Lifesciences Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore ERIS long-term asset investment ratio to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	Rs0.00	0%
Short-term Investments	Rs216.40 Million	0.29%
Total Liquid Assets	Rs216.40 Million	0.29%

Asset Resilience Insights

Limited Liquidity: Eris Lifesciences Limited maintains only 0.29% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Eris Lifesciences Limited Industry Peers by Asset Resilience Ratio

Compare Eris Lifesciences Limited's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Swedish Orphan Biovitrum AB (publ) ST:SOBI	Drug Manufacturers - Specialty & Generic	1.54%
Yunnan Baiyao Group Co Ltd SHE:000538	Drug Manufacturers - Specialty & Generic	8.38%
Guangdong Zhongsheng Pharmaceutical Co Ltd SHE:002317	Drug Manufacturers - Specialty & Generic	6.62%
Takeda Pharmaceutical Co Ltd ADR NYSE:TAK	Drug Manufacturers - Specialty & Generic	4.94%
Harbin Gloria Pharmaceuticals SHE:002437	Drug Manufacturers - Specialty & Generic	9.04%
Jiuzhitang Co Ltd SHE:000989	Drug Manufacturers - Specialty & Generic	7.86%
Renhe Pharmacy Co Ltd SHE:000650	Drug Manufacturers - Specialty & Generic	37.54%
Jiangsu Kanion Pharmaceutical Co Ltd SHG:600557	Drug Manufacturers - Specialty & Generic	0.29%

Annual Asset Resilience Ratio for Eris Lifesciences Limited (2012–2026)

The table below shows the annual Asset Resilience Ratio data for Eris Lifesciences Limited.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2026-03-31	0.29%	Rs216.40 Million ≈ $2.34 Million	Rs73.66 Billion ≈ $796.55 Million	+0.22pp
2025-03-31	0.07%	Rs50.00 Million ≈ $540.73K	Rs70.33 Billion ≈ $760.61 Million	-17.59pp
2024-03-31	17.66%	Rs12.45 Billion ≈ $134.60 Million	Rs70.49 Billion ≈ $762.30 Million	+16.75pp
2023-03-31	0.91%	Rs332.21 Million ≈ $3.59 Million	Rs36.67 Billion ≈ $396.61 Million	-6.26pp
2022-03-31	7.17%	Rs1.63 Billion ≈ $17.62 Million	Rs22.72 Billion ≈ $245.72 Million	+6.33pp
2021-03-31	0.84%	Rs153.99 Million ≈ $1.67 Million	Rs18.35 Billion ≈ $198.42 Million	-3.98pp
2020-03-31	4.82%	Rs747.81 Million ≈ $8.09 Million	Rs15.52 Billion ≈ $167.88 Million	-15.45pp
2019-03-31	20.27%	Rs3.15 Billion ≈ $34.06 Million	Rs15.54 Billion ≈ $168.02 Million	+13.85pp
2018-03-31	6.42%	Rs937.89 Million ≈ $10.14 Million	Rs14.60 Billion ≈ $157.90 Million	-33.90pp
2017-03-31	40.33%	Rs2.58 Billion ≈ $27.95 Million	Rs6.41 Billion ≈ $69.32 Million	+24.72pp
2016-03-31	15.61%	Rs653.20 Million ≈ $7.06 Million	Rs4.19 Billion ≈ $45.27 Million	-3.77pp
2015-03-31	19.38%	Rs692.40 Million ≈ $7.49 Million	Rs3.57 Billion ≈ $38.64 Million	-5.37pp
2014-03-31	24.75%	Rs669.64 Million ≈ $7.24 Million	Rs2.71 Billion ≈ $29.26 Million	-2.32pp
2013-03-31	27.07%	Rs465.00 Million ≈ $5.03 Million	Rs1.72 Billion ≈ $18.58 Million	+13.88pp
2012-03-31	13.18%	Rs134.52 Million ≈ $1.45 Million	Rs1.02 Billion ≈ $11.04 Million	--

pp = percentage points

About Eris Lifesciences Limited

NSE:ERIS India Drug Manufacturers - Specialty & Generic

Market Cap

$1.98 Billion

Rs183.11 Billion INR

Market Cap Rank

#6254 Global

#282 in India

Share Price

Rs1321.30

Change (1 day)

+0.81%

52-Week Range

Rs1271.00 - Rs1701.30

All Time High

Rs1847.70